Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.WT

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > PDT is the future of cancer treatment.
View:
Post by wildbird1 on Jun 25, 2024 3:01pm

PDT is the future of cancer treatment.

In this link...[url=https://ncbi,nlm.nih.gov/pmc/articles/PMC9913255/][/url]

3. Conclusions
'' As a non-invasive therapy method, PDT has obtained significant progress in recent years....Besides, based on the noninvasive operation and unique therapeutic mechanism,PDT can be perfectly combined with Chemotherapy, Radiotherapy, Immune therapy, and Gene therapy. It is beleived that with continuous optimization of photosensitizer, and PDT-based combined treatment system, PDT has a broader clinical application prospect in cancer treatment''.

IN conclusion..  The non-invasive therapy method, is what make PDT easy to use with other existing treatments. Once TLT-Ruvidar has been approved by the FDA, we could see a flurry of Big Pharma deals, to exploit the non-invasive characteristics of TLT-Ruvidar with other treatments.

TLT has just started to exploit the potential of PDT, the best is yet to come.
Comment by CancerSlayer on Jun 25, 2024 4:08pm
Thanks for sharing wildbird1... The simple reality is that patients deserve options.  Current options are not simple & require patient/time-intensive forms of treatment.  We offer optionality with a dose of versatility that could potentially boost outcomes while simplifying protocols.  JMO...
Comment by Legit62 on Jun 25, 2024 4:32pm
Your right cancerslayer, it should be about the patient, not Big Pharma profits
Comment by Legit62 on Jun 25, 2024 4:35pm
Unfortunately , big pharma always there, i had a career in medicine and they are always on your shoulder, pushing ,our technology is grate for patients. I hope one day this science works and patients get their wish
Comment by BlueFranky on Jun 25, 2024 4:22pm
Thanks wildbird1 .. appreciate your efforts as always!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250